Published in J Clin Psychopharmacol on June 01, 2010
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology (Berl) (2014) 0.84
What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress Anxiety (2011) 0.79
"I just start crying for no reason": the experience of stress and depression in pregnant, urban, African-American adolescents and their perception of yoga as a management strategy. Womens Health Issues (2015) 0.75
Treatment of anxiety in children and adolescents: using child and adolescent anxiety psychodynamic psychotherapy. Child Adolesc Psychiatr Clin N Am (2013) 0.75
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
The Health Belief Model: a decade later. Health Educ Q (1984) 25.48
Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol (1967) 22.39
Why people use health services. Milbank Mem Fund Q (1966) 14.55
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry (1999) 4.57
Selected psychosocial models and correlates of individual health-related behaviors. Med Care (1977) 3.07
Adequacy and duration of antidepressant treatment in primary care. Med Care (1992) 3.04
Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry (2003) 2.71
Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA (2002) 2.58
SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull (1986) 2.46
Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord (2000) 2.26
SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry (2001) 2.03
Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract (2006) 1.89
Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry (2001) 1.70
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry (2007) 1.67
Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry (2003) 1.62
Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry (2004) 1.52
Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry (1999) 1.45
Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother (2002) 1.44
The compliance with antidepressants in general practice. J Psychopharmacol (1994) 1.39
Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology (2007) 1.39
A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf (1997) 1.38
Tolerability and adherence issues in antidepressant therapy. Clin Ther (2003) 1.30
What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int J Neuropsychopharmacol (2008) 1.23
Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther (1999) 1.20
Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend (2007) 1.19
Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin (2006) 1.12
LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol (2000) 1.08
Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry (2005) 1.07
Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol (2008) 1.05
Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen Hosp Psychiatry (2005) 0.99
Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology (1999) 0.95
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther (2000) 0.89
Effects of acute and chronic tianeptine administration on serotonin outflow in rats: comparison with paroxetine by using in vivo microdialysis. Eur J Pharmacol (2000) 0.89
Pharmacological characterization of the 5-HT receptors mediating contraction and relaxation of canine isolated proximal stomach smooth muscle. Br J Pharmacol (2002) 0.87
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry (2005) 0.86
Identifying risk for attrition during treatment for depression. Psychother Psychosom (2009) 0.86
Early termination of antidepressant drug treatment. J Clin Psychopharmacol (2000) 0.84
Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf (2002) 0.84
Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety (2008) 0.83
Ketanserin attenuates the behavioural effects of corticosterone: implications for 5-HT(2A) receptor regulation. Eur J Pharmacol (2001) 0.76
Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives? Psychopharmacol Bull (1994) 0.76
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Surgery versus nonsurgical treatment of lumbar spinal stenosis: a randomized trial. Ann Intern Med (2015) 6.66
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Exercise treatment for depression: efficacy and dose response. Am J Prev Med (2005) 4.99
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol (2013) 4.20
Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry (2009) 3.96
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2008) 3.82
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry (2012) 3.73
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2008) 3.65
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry (2008) 3.40
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
Does bereavement-related major depression differ from major depression associated with other stressful life events? Am J Psychiatry (2008) 3.07
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J Psychiatr Res (2008) 3.01
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry (2013) 2.80
Complicated grief and related bereavement issues for DSM-5. Depress Anxiety (2011) 2.77
The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2006) 2.68
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry (2010) 2.52
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry (2005) 2.50
STAR*D: what have we learned? Am J Psychiatry (2007) 2.47
Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry (2010) 2.45
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry (2008) 2.42
Why do faculty leave? Reasons for attrition of women and minority faculty from a medical school: four-year results. J Womens Health (Larchmt) (2008) 2.34
Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA (2003) 2.30
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol (2008) 2.23
Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. Evid Based Complement Alternat Med (2007) 2.22
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury. Crit Care Med (2002) 2.21
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol (2004) 2.21